INOVSYNTHInnovassynth Technologies (India) Ltd.
Innovassynth Technologies (India) re-appoints Dr. Hardik Joshipura as MD and CEO
- Management change
- pharmaceuticals and fine chemicals
Reviewed byKeshav SehgalBlacklitt Research
Innovassynth Technologies (India) (NSE: INOVSYNTH) said in a filing on 02 Nov 2026 that its board has approved the re-appointment of Dr. Hardik Joshipura as Managing Director and CEO for a further three years, from 12 Feb 2027 to 11 Feb 2030, subject to shareholder approval.
The re-appointment and its terms
The board approved the re-appointment at its meeting on 02 Nov 2026, on the recommendation of the Nomination and Remuneration Committee and on the terms and conditions that committee recommended. The stated reason is the completion of Dr. Joshipura's existing tenure. He is liable to retire by rotation.
The term runs for three years, both days inclusive, and the re-appointment takes effect only once shareholders approve it. Dr.
Background of the managing director
The filing says Dr. Joshipura began his career at Zydus Cadila, where he led contract research R&D for the fine chemicals business. He later held senior leadership positions at Sigma-Aldrich and then at Merck KGaA, in manufacturing, sales and global strategic marketing.
He holds a Ph.D. in Organic Chemistry and completed an Executive MBA at Harvard Business School, Boston.
What the re-appointment means for Innovassynth Technologies (India)'s shareholders
The change keeps the current managing director and CEO in office for a further term, with no change of officer named in the filing. The re-appointment depends on shareholder approval, and the filing does not say when that meeting will be held or whether approval has been obtained.
The filing does not state the remuneration or other terms approved, or who would take over if shareholders do not approve the re-appointment.
At a glance
| Item | Detail |
|---|---|
| Officer | Dr. Hardik Joshipura, Managing Director and CEO |
| Board approval | 02 Nov 2026 |
| Term | Three years, 12 Feb 2027 to 11 Feb 2030 |
| Retire by rotation | Yes |
| Condition | Approval of shareholders |
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
